Skip to content

Shop
Scholar
Lab Results
Learn
Vote
Forum
About

Search Kodiac

Sign in Sign up Account

Author: kodiac

Ovagen

Our opinion on this compoundSingle-lab provenance

48/100

Single-lab Khavinson hepatic tripeptide with genuinely novel mechanism claims but zero independent validation

Here’s the thing about Ovagen: the mechanism story is genuinely interesting. A tripeptide that skips receptor signaling entirely and goes straight to the nucleus to interact with DNA promoter regions and reshape chromatin state for hepatocyte gene expression. Thats a bold claim. It’s the kind of mechanism that, if independently verified, would represent something meaningfully new in the hepatoprotective space. We don’t have anything quite like it from a Western-validated source, and that’s exactly why Ovagen is worth knowing about and also why a serious investigator needs to hold the evidence lightly.

Ovagen is the liver and GI-specific member of Khavinson’s synthetic ultrashort peptide line, a tripeptide sequence Glu-Asp-Leu (EDL) at 375 daltons. The Khavinson group’s working theory is that ultrashort peptides of this size can penetrate cell membranes without receptor-mediated endocytosis, localize to the nucleoplasm, and perform sequence-specific binding at promoter regions. For Ovagen, the reported effects include roughly 18-fold increases in Ki-67 (proliferation marker) and 6-fold decreases in p53 expression in aged rat liver tissue. That’s a large signal in a senescence model. Interesting if real.

The problem is the evidence base. Its Khavinson and collaborating Russian institutions, full stop. No independent replication. No human pharmacokinetic data to Western standards. No published, peer-reviewed clinical trials. That pattern will look familiar if you’ve looked at Epitalon or Thymalin from the same program. The proposed direct peptide-DNA interaction mechanism, while theoretically compelling, hasn’t been validated by structural biology methods that Western investigators would require: ChIP-seq, ATAC-seq, or crystal structure work showing actual peptide-DNA contact geometry are all absent from the published literature. The 2021 Molecules systematic review from Khavinson’s group covers the broader framework but doesn’t resolve the replication gap.

What we like about Ovagen as a research target is the mechanistic niche. If you’re running a program on epigenetic regulation of hepatic aging, or specifically testing whether ultrashort peptides can function as nuclear-localizing chromatin remodelers, Ovagen is a probe with no close analog in the Western catalog. That’s genuine bench value, limited but real. The gastrointestinal mucosal data, specifically tight junction expression and intestinal permeability effects in aging models, adds a secondary application angle that’s independently interesting given current attention on gut-liver axis biology.

What we don’t like: you’re building entirely on one lab’s work. The 14 to 28-day carbon tetrachloride and paracetamol hepatotoxicity models show signal, but CCl4 models are notoriously permissive and many compounds look plausible there. The absence of any human pharmacokinetic or efficacy signal means translational confidence is essentially zero at present. For investigators specifically curious about the Khavinson ultrashort peptide class or the peptide-DNA interaction hypothesis as a research object, Ovagen is worth examining. For anyone who needs human-translatable evidence before committing bench resources, the score reflects where this compound actually sits.

Novelty

65

Mechanism promise

70

In-category differentiation

55

Evidence quality

20

Translational signal

18

Research bench value

38

Rationale The direct peptide-DNA chromatin remodeling story is the most mechanistically novel angle in the hepatoprotective category, but the evidence base is entirely Khavinson-consortium preclinical with no human data and no independent replication, placing it firmly in the same evidentiary tier as Epitalon. Scores elevate slightly above Epitalon on mechanism novelty but are constrained by near-zero translational signal and the same single-source provenance problem.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Synthetic hepatoprotective tripeptide bioregulator of the Khavinson ultrashort peptide class

A synthetic tripeptide (Glu-Asp-Leu) developed at the Saint Petersburg Institute of Bioregulation and Gerontology as a tissue-specific epigenetic bioregulator targeting hepatic and gastrointestinal gene expression, distinguished from conventional hepatoprotective agents by a proposed mechanism of direct nuclear peptide-DNA interaction and chromatin remodeling rather than receptor-mediated signal transduction.

Abstract

Ovagen is a synthetic tripeptide composed of L-glutamic acid, L-aspartic acid, and L-leucine (Glu-Asp-Leu; single-letter code EDL) and belongs to the Khavinson class of ultrashort peptide bioregulators developed at the Saint Petersburg Institute of Bioregulation and Gerontology under the direction of Vladimir Khavinson. The compound is classified as a liver and gastrointestinal tract bioregulator within the Cytogen (synthetic short-chain peptide) product line and is proposed to exert its biological activity through direct interaction with nuclear DNA and chromatin rather than through conventional membrane receptor signaling. The molecular weight of Ovagen is 375.37 daltons (molecular formula C15H25N3O8), a size that places it within the ultrashort peptide category (2 to 7 amino acid residues) characterized by resistance to gastrointestinal peptidase degradation, oral bioavailability without enteric coating in some formulations, and the capacity to cross cellular membranes and localize to the nucleoplasm without receptor-mediated endocytosis. The principal proposed mechanism of action involves sequence-specific binding of the EDL tripeptide to double-stranded DNA in the promoter regions of hepatocyte genes governing cell proliferation, antioxidant defense, apoptosis, and inflammatory signaling. In aged rat liver tissue, Ovagen administration has been reported to produce an approximately 18-fold increase in Ki-67 expression (a marker of cellular proliferation) and an approximately 6-fold decrease in p53 expression (a marker of apoptotic signaling and cellular senescence), suggesting a shift from senescent to proliferative hepatocyte phenotype [1, 2]. In preclinical models of chemically induced hepatotoxicity (carbon tetrachloride and paracetamol), Ovagen administration over 14 to 28 days reduced serum liver enzyme elevation, decreased hepatocyte necrosis and inflammatory cell infiltration on histological examination, and normalized hepatic antioxidant status [3, 4]. A secondary research application involves gastrointestinal mucosal support, with preclinical data suggesting that Ovagen strengthens epithelial barrier function, increases tight junction protein expression, and reduces intestinal permeability in aging models [5]. The compound has not been approved by any national regulatory authority for therapeutic use. No published, peer-reviewed human clinical trials of Ovagen exist as of the date of this monograph. The evidence base is entirely preclinical (cell culture and rodent models) and is derived predominantly from the Khavinson laboratory and collaborating Russian institutions. The peptide bioregulator framework within which Ovagen was developed has produced a substantial body of Russian-language and English-language literature, including a 2021 systematic review of peptide regulation of gene expression published in the journal Molecules [6], but the framework has not been independently validated by Western regulatory-standard clinical trials. Investigators considering Ovagen for research applications should weight the evidence accordingly, noting the predominantly single-laboratory provenance of the preclinical data, the absence of human pharmacokinetic characterization to Western regulatory standards, and the mechanistic novelty of the proposed direct peptide-DNA interaction pathway. This monograph reviews the chemistry, proposed mechanism of action, preclinical pharmacology, available pharmacokinetic considerations, sourcing and quality verification, reconstitution and handling, stack-interaction considerations, adverse-event signal, and a comparative assessment of five hepatoprotective or liver-bioregulatory candidates against Ovagen on five competency standards.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1406Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 10, 2026
Octreotide

Our opinion on this compoundEstablished workhorse

52/100

The canonical SSTR2-selective reference compound, clinically mature with real bench utility but little frontier novelty

Look, octreotide is one of those compounds where the sheer weight of clinical evidence almost works against it as a research target. Bauer and colleagues at Sandoz synthesized SMS 201-995 in 1982, the FDA approved it in 1988, and by now the somatostatin receptor subtype 2 pharmacology it illuminated has been exhaustively characterized. We know the binding kinetics cold: Ki approximately 0.4 to 0.6 nanomolar at SSTR2, roughly 7 nanomolar at SSTR5, negligible at SSTR1 and SSTR4. The Gi-coupled downstream cascade, adenylyl cyclase inhibition, reduced cAMP, suppression of GH and the splanchnic peptide circus, its all textbook material at this point.

What octreotide genuinely has going for it is bench value as a reference probe. If you’re doing SSTR subtype selectivity work, you need octreotide in the comparison panel. The PROMID trial data (Rinke et al. 2009, HR 0.34, p equal to 0.000072 on time to tumor progression in midgut NETs) is clean and credible. The PK record after subcutaneous dosing, peak at 25 to 30 minutes, bioavailability near 100 percent, t1/2 roughly 90 to 120 minutes, is mature enough to serve as a reference standard for half-life extension strategies in the cyclic peptide space. The 2020 oral Mycapssa approval is genuinely interesting from a formulation-science angle, even if the compound underneath is old news.

Here’s the thing though: the research frontier in the somatostatin axis has moved. Pasireotide, with its broader SSTR1/2/3/5 profile, is the more interesting pharmacological object for investigators interested in Cushing’s disease and escape mechanisms. Lu-177 DOTATATE has repositioned the entire NET field around theranostic radiopharmaceuticals, and the octreotide scaffold underpins that ligand family as a structural starting point rather than a target in its own right. Paltusotine is the oral non-peptide SSTR2 agonist that will eventually displace octreotide in clinical maintenance, and it raises much more interesting SAR questions. Octreotide itself is mostly the molecule you reach for when you need to define what SSTR2-selective engagement looks like, not the molecule anyone is running a serious exploratory program around in 2026.

We think its place in a research library is legitimate but specific: its a comparator, a reference point, a structural ancestor. The evidence quality and translational signal scores are high because decades of human data dont lie. But the novelty and mechanism scores honestly reflect that theres very little left to discover here. Serious bench investigators in the somatostatin space will use it; they just wont be excited about it.

Novelty

22

Mechanism promise

38

In-category differentiation

50

Evidence quality

78

Translational signal

78

Research bench value

62

Rationale Octreotide scores strongly on evidence and translational signal because it is an FDA-approved drug with replicated phase 3 data and decades of clinical use, but those same facts drive novelty and mechanism scores to the floor. The compound is 40+ years old and the SSTR2 pharmacology it opened is now thoroughly characterized; the primary research question for the field has shifted to broader-subtype agents, radiolabeled conjugates, and oral non-peptide agonists, leaving octreotide as an indispensable reference probe rather than a live research frontier.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Synthetic cyclic octapeptide somatostatin analog with preferential binding to somatostatin receptor subtypes 2 and 5

A disulfide-bridged octapeptide analog of hypothalamic somatostatin-14 developed at Sandoz as SMS 201-995, distinguished from the native hormone by a 30-fold increase in inhibition of growth hormone release relative to insulin suppression and an elimination half-life extended from under 3 minutes to approximately 100 minutes after subcutaneous administration.

Abstract

Octreotide (SMS 201-995) is a synthetic cyclic octapeptide analog of somatostatin-14 that reproduces the pharmacologically essential tetrapeptide core (Phe-Trp-Lys-Thr) of the native hormone within a conformationally constrained disulfide-bridged ring, yielding a compound with high-affinity binding at somatostatin receptor subtype 2 (SSTR2; Ki approximately 0.4 to 0.6 nanomolar), moderate affinity at SSTR5 (Ki approximately 7 nanomolar) and SSTR3 (Ki approximately 35 nanomolar), and negligible affinity at SSTR1 and SSTR4 [1, 2]. The compound was synthesized at the Sandoz Forschungsinstitut in Basel by Bauer, Briner, Doepfner, and colleagues in 1982, selected from a series of conformationally stabilized somatostatin fragments on the basis of a 45-fold increase in potency for growth hormone inhibition relative to somatostatin-14 in an in vitro rat pituitary bioassay and a 30-fold selectivity for growth hormone suppression over insulin suppression, a therapeutic index absent from the native tetradecapeptide [1]. The critical structural innovation was the introduction of a D-Trp at position 4 and D-phenylalanol at the C-terminus within a cystine-bridged octapeptide ring that resisted enzymatic degradation and extended the plasma elimination half-life from the approximately 1 to 3 minutes of native somatostatin to approximately 90 to 120 minutes after subcutaneous injection in humans [3, 4]. Octreotide received United States Food and Drug Administration approval in 1988 for the symptomatic management of acromegaly and for the control of symptoms associated with metastatic carcinoid tumors and vasoactive intestinal peptide-secreting tumors (VIPomas). The long-acting release (LAR) intramuscular depot microsphere formulation (Sandostatin LAR, Novartis) was approved in 1998, enabling once-monthly administration at 10, 20, or 30 milligram doses. An oral octreotide capsule formulation (Mycapssa, Chiasma/Amryt) employing a transient permeability enhancer technology received FDA approval in 2020 for long-term maintenance therapy in acromegaly patients previously responding to injectable somatostatin receptor ligands [5]. The antiproliferative activity of octreotide LAR in metastatic midgut neuroendocrine tumors was established in the PROMID trial (Rinke et al. 2009), a placebo-controlled randomized study demonstrating a median time to tumor progression of 14.3 months versus 6.0 months on placebo (hazard ratio 0.34, p equal to 0.000072) [6]. Pharmacokinetics after subcutaneous administration are characterized by rapid absorption (peak plasma concentration at 25 to 30 minutes), high bioavailability (approximately 100 percent), plasma protein binding of approximately 65 percent predominantly to lipoprotein, hepatobiliary metabolism, and renal elimination of approximately 32 percent of the dose as unchanged drug [3, 4]. The principal adverse effects are gastrointestinal (diarrhea, nausea, abdominal discomfort in 30 to 50 percent of patients, typically self-limiting), cholelithiasis (gallstone or biliary sludge formation in 15 to 30 percent on chronic therapy, attributable to inhibition of cholecystokinin-mediated gallbladder contraction and bile flow), and alterations in glucose homeostasis (suppression of insulin and glucagon secretion producing hyper- or hypoglycemia depending on the metabolic context) [7, 8]. This monograph documents the chemistry, synthesis, and structural pharmacology of octreotide; the somatostatin receptor subtype binding profile and downstream signaling; the comprehensive human pharmacokinetic record across subcutaneous, intramuscular depot, and oral formulations; the clinical evidence base across acromegaly, neuroendocrine tumors, carcinoid syndrome, VIPomas, variceal bleeding, and investigational indications; reconstitution and handling; stack-interaction considerations; the adverse-event and safety record; and a structured comparative assessment of five somatostatin-pathway agents (lanreotide, pasireotide, pegvisomant, paltusotine, lutetium-177 DOTATATE) against octreotide on five competency standards.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1390Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 10, 2026
Nafarelin

Our opinion on this compoundEstablished workhorse

40/100

Mature FDA-approved GnRH superagonist with intranasal uniqueness but limited modern research frontier value

Look, nafarelin is a genuinely interesting piece of peptide chemistry history, but interesting history and compelling research target in 2026 are two different things. The D-3-(2-naphthyl)alanine substitution at position 6 was clever when the Syntex peptide chemistry group built it in the early 1980s: it solved the aminopeptidase stability problem and pushed receptor affinity approximately 200-fold above native GnRH. That work directly informed the broader structure-activity program that produced the entire GnRH superagonist class. We appreciate the chemistry. It was good chemistry.

The problem is that the mechanism is now completely characterized, the clinical picture is mature, and the class itself is well-populated with alternatives. GnRH receptor desensitization through continuous agonism is textbook pharmacology. There’s no ambiguity about what’s happening: continuous gonadotrope stimulation downregulates receptor expression within two to four weeks and drives LH and FSH output to castrate or prepubertal levels. The tissue-level estradiol and testosterone suppression that follows is predictable and well-documented. That’s clean pharmacology, but it’s not a research frontier by any definition the rubric is trying to reward.

Within the class, nafarelinss one real claim to differentiation is the intranasal route. Its the only GnRH agonist delivered exclusively by nasal spray in clinical practice, and there’s a small but legitimate use-case for non-injectable pituitary suppression in IVF protocols and for patient preference in CPP management. But that’s an operational characteristic, not a mechanistic edge. For researchers working on GnRH pulse frequency pharmacology, hypothalamic-pituitary axis signaling, or receptor internalization kinetics, leuprolide acetate has a far denser research footprint and is the workhorse used in most model designs. For pediatric CPP, histrelin’s implant pharmacokinetics make it the more tractable study tool.

What nafarelin does have going for it is evidence quality. Approved 1990, decades of head-to-head comparisons against goserelin and leuprolide in endometriosis and ART, a well-characterized safety profile including the bone mineral density time-course data from the 6-month endometriosis trials. The 2.8 percent intranasal bioavailability is precisely characterized, which is actually useful if youre specifically studying intranasal peptide delivery. That evidence base is real. But it cuts both ways: an approved drug with thoroughly worked-out pharmacology in a crowded class mostly means there isn’t much left to discover.

Honestly, the places nafarelin still earns bench attention are specific and narrow. If you’re building a GnRH receptor desensitization model and need a non-injectable agonist with known kinetics, it works. If you’re doing comparative intranasal peptide absorption work, the nafarelin pharmacokinetic dataset is a legitimate reference. Beyond that, we think investigator time is better spent on compounds where the mechanism, the indication space, or the receptor pharmacology is still actively being defined. Nafarelin is a solved problem. Good for it.

Novelty

18

Mechanism promise

20

In-category differentiation

38

Evidence quality

73

Translational signal

70

Research bench value

38

Rationale Nafarelin is a 1990-approved GnRH superagonist in a fully saturated drug class with completely characterized mechanism and well-established clinical profile; the intranasal delivery route is unique within the class but confers no mechanistic novelty, and leuprolide dominates research use, leaving investigators little uncharted territory to work with.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Gonadotropin-releasing hormone superagonist decapeptide with pituitary GnRH receptor desensitization activity

A synthetic decapeptide analog of gonadotropin-releasing hormone bearing a D-3-(2-naphthyl)alanine substitution at position 6, developed at Syntex Research as an intranasal GnRH superagonist approximately 200-fold more potent than native GnRH, FDA-approved for endometriosis and central precocious puberty through sustained pituitary gonadotrope desensitization and consequent suppression of gonadal steroidogenesis.

Abstract

Nafarelin (5-oxo-L-prolyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-3-(2-naphthyl)-D-alanyl-L-leucyl-L-arginyl-L-prolyl-glycinamide; CAS 76932-56-4 free base; molecular formula C66H83N17O13; molecular weight 1322.47) is a synthetic decapeptide superagonist analog of gonadotropin-releasing hormone (GnRH) that achieves approximately 200-fold greater receptor affinity than the native decapeptide through substitution of the bulky hydrophobic D-3-(2-naphthyl)alanine residue at position 6, conferring both enhanced receptor binding and resistance to aminopeptidase degradation. Developed at Syntex Research in the early 1980s and approved by the United States Food and Drug Administration on February 13, 1990 as Synarel (nafarelin acetate nasal solution), the compound was the first new pharmacotherapy for endometriosis to enter the US market in 14 years and remains the only GnRH agonist administered exclusively by intranasal spray in clinical practice. The mechanism of action follows the class pharmacology of GnRH superagonists: acute administration produces an initial stimulatory flare of luteinizing hormone and follicle-stimulating hormone release from anterior pituitary gonadotropes, followed within 2 to 4 weeks of continuous twice-daily intranasal dosing by profound receptor desensitization, downregulation of GnRH receptor expression, and consequent suppression of gonadotropin secretion to castrate or prepubertal levels, with parallel suppression of ovarian estradiol to postmenopausal concentrations (less than 20 pg/mL) or testicular testosterone to castrate concentrations. The resulting pharmacological hypoestrogenism or hypogonadism underlies the established clinical applications: management of pelvic pain and reduction in size and number of endometriotic implants in women 18 years and older (400 micrograms daily by intranasal spray for 6 months), and suppression of pubertal development in children with central precocious puberty (1600 micrograms daily by intranasal spray). An additional established clinical application is pituitary downregulation prior to controlled ovarian hyperstimulation in assisted reproductive technology cycles, where nafarelin produces pituitary suppression equivalent to leuprolide and triptorelin with the operational advantage of non-injectable self-administration. Pharmacokinetics after intranasal administration are characterized by rapid absorption through the nasal mucosa (peak plasma concentration at 10 to 40 minutes), low absolute bioavailability of approximately 2.8 percent (range 1.2 to 5.6 percent), plasma protein binding of 80 percent, metabolism by tissue peptidases rather than hepatic cytochrome P450 enzymes, and an elimination half-life of 2.5 to 3.0 hours by the intranasal route. The compound is well tolerated within the constraints of its mechanism: the principal adverse events are the predictable consequences of pharmacological hypoestrogenism (hot flashes in up to 90 percent of adult patients, decreased bone mineral density of 3 to 6 percent over 6 months of treatment with partial but incomplete reversal on cessation, vaginal dryness, decreased libido, emotional lability) and local nasal irritation (approximately 10 percent). The bone mineral density concern limits treatment duration to 6 months in the registered endometriosis indication without add-back therapy. This monograph reviews the chemistry, synthesis, and structure-activity relationships of nafarelin; the GnRH receptor pharmacology and desensitization mechanism; comprehensive pharmacokinetics; the clinical evidence base across endometriosis, central precocious puberty, assisted reproduction, uterine leiomyomas, and investigational applications; sourcing and quality verification; reconstitution and handling; stack interactions; adverse-event profile; and a comparative assessment of five GnRH agonist alternatives against nafarelin on five competency standards.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1396Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 10, 2026
Relamorelin

Our opinion on this compoundEstablished, active research

53/100

A potent, PK-optimized GHSR-1a agonist with real Phase 2 gastroparesis data, orphaned after AbbVie’s acquisition of Allergan

Look, relamorelin’s position in the research landscape comes down to one thing: it’s a well-engineered synthetic fix for a real limitation of native ghrelin. The ghrelin receptor system has been characterized since the late 1990s, and GHSR-1a agonism for GI motility has been explored for over two decades. What relamorelin brings is a synthetic pentapeptide that addressed the practical problems with native ghrelin, primarily its abysmal plasma stability (half-life of minutes in vivo) and modest receptor potency. The three-to-sixfold binding advantage over native ghrelin isnt trivial, and a terminal half-life of 4.5 to 19.4 hours depending on dose makes it viable for subcutaneous dosing protocols in a way that native ghrelin simply isnt.

The clinical evidence base is real, and that separates relamorelin from most of the peptide research space. Shin et al. 2016 and Camilleri et al. 2017 are Phase 2 RCTs, multicenter, randomized, with prespecified endpoints, showing 60 to 75 percent reduction in vomiting frequency and an 8-to-11-minute acceleration of gastric emptying half-time versus placebo in diabetic gastroparesis populations with objectively confirmed delayed emptying. The Fazeli 2018 anorexia nervosa proof-of-concept adds a legitimate if small signal: median gastric emptying time of 58 versus 85 minutes after four weeks. Across three indications and multiple Phase 2 programs, the GHSR-1a motility signal held up consistently.

The termination of PLEDGE in September 2020 is the defining liability here. AbbVie killed the Phase 3 after acquiring Allergan, a portfolio decision rather than an efficacy failure. The biology didn’t collapse under scrutiny. What investigators are dealing with is an orphaned program with real clinical signal and no current sponsor, which is a categorically different situation than a compound whose primary mechanism failed or whose Phase 3 missed its endpoints.

As a research tool, relamorelin is the most potent and PK-stable selective GHSR-1a agonist available at research grade with actual clinical characterization behind it. If your work involves ghrelin receptor biology, enteric nervous system function, interstitial cells of Cajal, gastroparesis models, or growth hormone secretagogue pharmacology, this is the most thoroughly characterized compound in that class. Camicinal (GSK962040) is a structural comparator but carries shallower Phase 2 data. Native ghrelin is impractical for most in vivo protocols. Ipamorelin and hexarelin hit GHSR-1a but without the gastrocolokinetic depth that relamorelin’s clinical program established.

What we dont love: the mechanism is not novel in 2026. GHSR-1a has been in the literature for close to 30 years. The differentiated angle is pharmacological optimization, better PK and potency, not new biology. For investigators tracking the frontier, MOTS-c, klotho-axis peptides, and triple incretin pharmacology represent more interesting territory. Relamorelin is solid, well-characterized, and clinically tested for its receptor class. Useful as a probe, honest about what it is.

Novelty

38

Mechanism promise

50

In-category differentiation

55

Evidence quality

60

Translational signal

62

Research bench value

60

Rationale Relamorelin earns established-active status on the strength of multi-indication Phase 2 RCT data and superior PK versus native ghrelin, but novelty scores are depressed by a receptor class that has been in the literature since the 1990s; the PLEDGE termination was portfolio-driven, not an efficacy signal.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Synthetic pentapeptide ghrelin receptor (GHSR-1a) agonist with gastrocolokinetic and growth hormone secretagogue activity

A synthetic pentapeptide ghrelin analog developed as a selective growth hormone secretagogue receptor agonist with approximately sixfold greater potency than native ghrelin, advanced through Phase 2 and Phase 3 clinical trials for diabetic gastroparesis, chronic idiopathic constipation, and anorexia nervosa.

Abstract

Relamorelin (RM-131, BIM-28131) is a synthetic pentapeptide analog of ghrelin that activates the growth hormone secretagogue receptor type 1a (GHSR-1a) with approximately three- to sixfold greater binding affinity and functional potency than native human ghrelin, and with substantially enhanced plasma stability and a terminal elimination half-life of approximately 4.5 to 19.4 hours depending on dose and measurement interval. The compound was originally synthesized by Ipsen as BIM-28131 and subsequently developed by Rhythm Pharmaceuticals (as RM-131), Motus Therapeutics, Allergan, and AbbVie for gastrointestinal motility disorders, principally diabetic gastroparesis, chronic idiopathic constipation, and anorexia nervosa. Relamorelin accelerates gastric emptying through activation of ghrelin receptors expressed on enteric neurons, interstitial cells of Cajal, and gastric smooth muscle, producing dose-dependent increases in antral contractile frequency and propagated colonic contractions without inhibition of gastric accommodation or induction of early satiation. In nonclinical studies, the compound reversed morphine-induced gastroparesis in Sprague-Dawley rats at potencies approximately 100-fold greater than native ghrelin and stimulated gastrointestinal transit throughout the small and large intestine. In clinical trials, relamorelin administered subcutaneously at 10 to 100 micrograms once or twice daily significantly accelerated gastric emptying half-time (mean difference of approximately 8 to 11 minutes versus placebo), reduced vomiting frequency by approximately 60 to 75 percent in diabetic gastroparesis populations with documented delayed gastric emptying, and improved composite symptom scores for nausea, bloating, abdominal pain, and early satiety. A Phase 2 trial in chronic idiopathic constipation demonstrated significant acceleration of colonic transit at 32 and 48 hours and increased spontaneous bowel movement frequency over 14 days of treatment. A proof-of-concept randomized trial in outpatient women with anorexia nervosa demonstrated significant reduction in gastric emptying time (median 58 versus 85 minutes) and a trend toward weight gain after four weeks of treatment. The principal adverse events observed across clinical programs were hyperglycemia (reflecting accelerated nutrient delivery to the small intestine in diabetic populations), diarrhea, headache, and dizziness, with no clinically significant injection site reactions. Growth hormone, prolactin, and cortisol elevations were observed as expected pharmacodynamic consequences of GHSR-1a activation. Allergan initiated a Phase 3 program (PLEDGE) comprising two pivotal 12-week randomized controlled trials in diabetic gastroparesis beginning in 2018; however, in September 2020, the program was terminated following the AbbVie acquisition of Allergan, and the compound is not currently in active clinical development. Relamorelin is not approved by any regulatory authority. It remains available as a research-grade compound from multiple chemical suppliers and is the subject of ongoing academic interest as both a pharmacological tool for ghrelin receptor biology and a potential therapeutic candidate for gastrointestinal dysmotility syndromes. This monograph reviews the chemistry, structure, and synthesis of relamorelin; the molecular pharmacology at the GHSR-1a receptor; comprehensive pharmacokinetics; preclinical gastrointestinal pharmacology; the clinical evidence base across diabetic gastroparesis, chronic constipation, and anorexia nervosa indications; sourcing and quality verification; reconstitution and handling; stack interactions; adverse events and safety signals; and a comparative assessment of five gastroparesis therapeutic candidates against relamorelin on five competency standards.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1421Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 10, 2026
Cardiogen

Our opinion on this compoundSingle-lab provenance

39/100

A Khavinson cardiac tetrapeptide with a compelling epigenetic mechanism claim and zero independent validation

Look, Cardiogen is the Khavinson group’s cardiac ticket, and if you’ve spent any time with Epitalon or Cortagen you already know what that means: serious mechanistic ambition paired with a near-total absence of independent verification. The compound is the AEDR tetrapeptide (Ala-Glu-Asp-Arg), differing from its pineal cousin Epitalon only at the fourth-position residue, where glycine gives way to arginine. That single substitution is the claimed basis for cardiac tissue specificity within the Khavinson classification system. Appealing, if true.

The mechanism story is the most interesting thing here. Khavinson’s group characterizes Cardiogen as an epigenetic regulator that directly interacts with double-stranded DNA at promoter regions and with histone proteins H1, H2B, H3, and H4, producing chromatin decondensation and reactivation of transcriptional programs in cardiomyocytes. Thats a bold claim for a four-residue linear peptide, and honestly the molecular modeling supporting it is thought-provoking. The reported preclinical outputs include cytoskeletal protein upregulation (actin, vimentin, tubulin up to fivefold), nuclear matrix protein increases (lamin A/C to 2.5x control), anti-apoptotic activity via p53 downregulation, and a threefold reduction in mortality in a coronary artery ligation rat model. Those numbers are striking. They are also entirely from one address.

Here’s the thing about single-consortium data: it’s not worthless, but it creates an evidence gap that no amount of mechanistic elegance can bridge. We don’t have a single replication study from an independent lab. We don’t have a human trial, not even a small pilot. The Russian registration as a biologically active additive doesn’t signal clinical validation; it signals the Russian regulatory classification that applies to this entire compound category. Pharmacokinetics are modeled rather than measured for the isolated AEDR peptide, and while the PEPT1/PEPT2 transporter argument for ultrashort peptide absorption is scientifically reasonable, it remains theoretical for this specific compound.

What we do like is the mechanistic specificity of the chromatin angle. Direct peptide-histone and peptide-DNA promoter interaction as a driver of tissue-specific transcriptional reactivation in post-ischemic cardiac cells is a genuinely underexplored research question. If this mechanism holds up outside Saint Petersburg, the implications for myocardial repair biology are real. The tumor-modifying data on M-1 sarcoma in senescent rats is an interesting side observation, though the proposed vascular/hemorrhagic-necrosis mechanism there needs independent examination before it means much.

Where Cardiogen lands: it’s more mechanistically interesting than Epitalon and the cardiac ischemia indication carries cleaner translational relevance than longevity biomarkers, but the evidentiary situation is functionally identical to its family members. Single lab, zero human data, no replication. The score reflects what the evidence actually supports, not what the mechanism might eventually deliver if someone outside Russia picks it up.

Novelty

52

Mechanism promise

55

In-category differentiation

42

Evidence quality

22

Translational signal

20

Research bench value

30

Rationale Cardiogen occupies the same single-consortium zone as Epitalon, with the Khavinson group providing all published data and no independent replication outside Saint Petersburg; the direct peptide-chromatin interaction mechanism is the most genuinely interesting element but remains unverified by any external lab. Evidence quality and translational signal scores pull the overall down despite moderate novelty and mechanism scores.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Synthetic cardioprotective tetrapeptide bioregulator with epigenetic gene-regulatory and anti-apoptotic activity targeting cardiomyocytes

A synthetic tetrapeptide (H-Ala-Glu-Asp-Arg-OH; AEDR) developed at the Saint Petersburg Institute of Bioregulation and Gerontology as an ultrashort peptide bioregulator with cardioprotective, anti-apoptotic, and epigenetic chromatin-regulatory activity targeting cardiomyocytes, cardiac fibroblasts, and myocardial gene expression programs.

Abstract

Cardiogen (H-Ala-Glu-Asp-Arg-OH; AEDR tetrapeptide; molecular formula C18H31N7O9; molecular weight 489.48 g/mol) is a synthetic tetrapeptide bioregulator developed by Vladimir Khavinson and colleagues at the Saint Petersburg Institute of Bioregulation and Gerontology as the cardiac-specific member of the Khavinson ultrashort peptide bioregulator family [1, 2]. The compound belongs to a class of synthetic two-to-seven-residue peptide sequences modeled on tissue-specific peptide fragments isolated from mammalian organ extracts, and is designated as the cardiovascular system bioregulator within this peptide family. Cardiogen shares the Ala-Glu-Asp tripeptide core with the cortical bioregulator Cortagen (Ala-Glu-Asp-Pro) and the pineal bioregulator Epithalon (Ala-Glu-Asp-Gly), differing from these compounds by the fourth-position arginine residue, a single amino acid substitution that determines cardiac tissue specificity within the Khavinson classification system [3, 4]. The principal molecular mechanism of Cardiogen, characterized through molecular modeling, cell culture, and organotypic myocardial tissue studies, is epigenetic regulation of gene expression through direct interaction of the tetrapeptide with double-stranded DNA in gene promoter regions and with histone proteins (H1, H2B, H3, H4), producing chromatin decondensation and reactivation of transcriptional programs in cardiac cells [5, 6, 7]. The cardioprotective activity, characterized in organotypic myocardial tissue cultures, embryonic fibroblast cultures, and coronary artery ligation animal models, includes stimulation of cardiomyocyte proliferation with concurrent suppression of cardiomyocyte apoptosis through p53 protein downregulation, upregulation of cytoskeletal proteins (actin, vimentin, tubulin) by up to five-fold and nuclear matrix proteins (lamin A, lamin C) by up to 2.5-fold relative to control, preservation of myocardial glycogen stores and cellular energy production structures under ischemic conditions, and a reported threefold reduction in mortality following experimental coronary artery ligation in treated versus control groups [8, 9, 10, 11]. In a separate line of investigation, Cardiogen demonstrated tumor-modifying activity against transplanted M-1 sarcoma in senescent rats, with dose-dependent inhibition of tumor growth mediated by hemorrhagic necrosis and stimulation of tumor cell apoptosis through a vascular mechanism rather than direct cytostatic effect [12]. The compound has been characterized in the context of the senescence-associated secretory phenotype of cardiovascular system cells and inflammaging, with evidence that the AEDR tetrapeptide regulates molecules involved in the inflammatory pathways contributing to age-related cardiovascular decline [13]. No formal pharmacokinetic studies have been published for Cardiogen as the isolated synthetic AEDR tetrapeptide. As a linear tetrapeptide with unprotected termini, the compound is expected to undergo rapid proteolytic degradation by aminopeptidases and carboxypeptidases in plasma and gastrointestinal fluid; however, molecular modeling studies have demonstrated that ultrashort peptides are substrates of the proton-coupled oligopeptide transporter (PEPT1/PEPT2) family carriers, supporting intestinal absorption and cellular uptake through active transport mechanisms [14, 15]. No human clinical trials have been published. The compound is not approved by the United States Food and Drug Administration, the European Medicines Agency, or any major Western regulatory authority. Cardiogen is registered in the Russian Federation as a biologically active additive and is commercially available there in capsule and sublingual formulations. It is supplied internationally as a research-grade lyophilized peptide by multiple peptide synthesis vendors at greater than 95 percent purity by high-performance liquid chromatography. This monograph reviews the chemistry, synthesis, and structural characterization of Cardiogen; the discovery and development history within the Khavinson bioregulatory peptide program; the molecular pharmacology including peptide-DNA binding, histone interaction, and cardiac gene expression modulation; the pharmacokinetic considerations for ultrashort peptides; the preclinical pharmacology across cardiac, inflammatory, and aging cell models; the clinical evidence base (absent); sourcing and quality verification; reconstitution and handling; stack interactions and combinations; adverse events and safety signal; and a comparative assessment of five cardioprotective or cardiac-repair peptide candidates (Vesugen, Thymosin beta-4, BPC-157, Cortagen, GHK-Cu) against Cardiogen on five competency standards.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1402Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 10, 2026
Histrelin

Our opinion on this compoundEstablished workhorse

45/100

Mature GnRH superagonist with highest class binding affinity but solved biology and limited frontier research value

Look, histrelin sits in an interesting position: genuinely best-in-class on two metrics that matter (receptor binding affinity and dosing interval), but competing in a pharmacological space the bench research community largely moved past in the 1990s. The compound was developed at Ortho Pharmaceutical in the early 1980s, and while the once-yearly hydrogel implant reformulation was a real delivery-system innovation when Supprelin LA and Vantas launched, the underlying GnRH receptor pharmacology is textbook material at this point. The biphasic agonist-then-suppression mechanism is elegant. The Gq/11-PLC uncoupling, receptor internalization, and transcriptional downregulation of GnRH receptor expression are well-characterized. Thats not a knock on the compound; it just means theres not much left to discover there for most investigators.

What makes histrelin worth benchmarking against leuprolide, goserelin, and the rest is the D-His(Bzl) substitution at position 6, which eliminates the principal endopeptidase cleavage site and introduces hydrophobic receptor contacts that push binding affinity to 100- to 200-fold above native GnRH, the highest in the clinical class. In research settings where you need reliable, sustained HPG axis suppression with a single administration, that affinity profile is genuinely useful. But most bench investigators reach for leuprolide or degarelix first because sourcing is more predictable and the literature is considerably denser.

The evidence quality is real. Two FDA approvals, multiple phase 2/3 trials, a clean pediatric pharmacokinetic dataset in the CPP population, steady-state implant concentrations well-characterized at 0.2 to 0.4 ng/mL. The translational signal is unambiguous: medical castration is achieved reliably, and the CPP data are as clean as clinical endocrinology gets. We’re not questioning efficacy.

What we’re questioning is whether this is a frontier research target. Honestly, it isn’t. The action in the GnRH space right now is in the antagonists, particularly relugolix (oral, no flare, rapidly reversible, cardiovascular signal in phase 3), which is generating genuinely new clinical questions and eating into the agonist market. The agonist mechanism, including histrelin’s version of it, is solved biology for most investigators. If you’re building an HPG axis suppression model, histrelin works. If you’re studying GnRH receptor pharmacology and need a high-affinity probe, its binding characteristics give it niche utility. But it’s not where serious endocrinology or reproductive biology researchers are pointing their attention.

Vantas was discontinued in 2020 for manufacturing reasons, which narrows the compound’s clinical footprint to the CPP indication. Supprelin LA remains available, but CPP research generates modest interest compared to the metabolic and oncology frontiers. What you’re left with is a well-validated, high-affinity GnRH superagonist with a distinguished clinical record, a genuinely distinctive delivery system, and limited bench-level novelty. Worth having in a reference library; not the compound an investigator should build a program around today.

Novelty

20

Mechanism promise

32

In-category differentiation

52

Evidence quality

68

Translational signal

72

Research bench value

28

Rationale Histrelin earns real credit for its position-6 D-His(Bzl) substitution and 100- to 200-fold potency advantage, plus a genuinely distinctive once-yearly implant delivery system, but the GnRH receptor desensitization mechanism is textbook-level understood and the research frontier has clearly moved to antagonists. Evidence quality and translational signal are strong (two FDA approvals, clean PK record), but novelty and bench probe value are low for most investigators.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Synthetic gonadotropin-releasing hormone superagonist nonapeptide with sustained pituitary-gonadal axis suppression through GnRH receptor desensitization and downregulation

A synthetic nonapeptide analog of endogenous gonadotropin-releasing hormone bearing a D-histidine(N-benzyl) substitution at position 6 and an ethylamide C-terminal modification, conferring approximately 100- to 200-fold greater potency than native GnRH and marked resistance to enzymatic degradation, developed at Ortho Pharmaceutical in the early 1980s and now FDA-approved as a once-yearly subcutaneous hydrogel implant for advanced prostate cancer (Vantas, approved 2004, discontinued 2020) and central precocious puberty (Supprelin LA, approved 2007), distinguished from other GnRH agonists by the highest binding affinity in the clinical class and the longest approved dosing interval achieved through a diffusion-controlled hydrogel polymer reservoir delivery system.

Abstract

Histrelin (pGlu-His-Trp-Ser-Tyr-D-His(Bzl)-Leu-Arg-Pro-NHEt; CAS 76712-82-8, free base; molecular formula C66H86N18O12; molecular weight 1323.53) is a synthetic nonapeptide analog of the hypothalamic decapeptide gonadotropin-releasing hormone (GnRH, also designated luteinizing hormone-releasing hormone, LHRH) distinguished from other members of the clinical GnRH agonist class by exceptionally high receptor binding affinity and by a unique formulation as a once-yearly subcutaneous hydrogel polymer implant [1, 2]. The compound incorporates two structural modifications to native GnRH that collectively confer superagonist potency and metabolic stability: replacement of glycine at position 6 with D-histidine bearing an N-benzyl substituent on the imidazole ring, which eliminates the principal endopeptidase cleavage site and introduces a bulky aromatic moiety favorable to hydrophobic interaction with the GnRH receptor transmembrane domain; and replacement of the C-terminal glycinamide (position 10) with an ethylamide, which further resists carboxypeptidase degradation [3, 4]. The resulting peptide binds the type I GnRH receptor with affinity approximately 100- to 200-fold greater than native GnRH and produces the characteristic biphasic pharmacological response common to all GnRH superagonists [5, 6]. Acute administration stimulates pituitary gonadotroph secretion of luteinizing hormone and follicle-stimulating hormone, producing transient elevations in gonadal steroid output (the “flare” phase, lasting 7 to 14 days). Chronic continuous administration produces homologous desensitization of the GnRH receptor through receptor internalization, uncoupling from Gq/11-phospholipase C signaling, and transcriptional downregulation of GnRH receptor expression, resulting in profound and sustained suppression of gonadotropin secretion and a hypogonadal state equivalent to surgical castration in both sexes [5, 6, 7]. Histrelin was initially developed at Ortho Pharmaceutical Corporation (a Johnson and Johnson subsidiary) in the early 1980s and studied in daily subcutaneous injection formulations for central precocious puberty, prostate cancer, and endometriosis [8, 9]. The compound was subsequently reformulated by Roberts Laboratories (later acquired by Shire Pharmaceuticals, then Endo Pharmaceuticals) into a diffusion-controlled hydrogel polymer reservoir subcutaneous implant delivering approximately 65 micrograms of histrelin acetate per day over 12 months [10, 11]. This implant technology produced two FDA-approved products: Vantas (50 mg histrelin acetate implant for palliative treatment of advanced prostate cancer, approved October 2004) and Supprelin LA (50 mg histrelin acetate implant for central precocious puberty, approved May 2007) [12, 13]. Vantas was discontinued in 2020 owing to manufacturing quality issues at the production facility; Supprelin LA remains commercially available. Pharmacokinetics of the implant formulation are characterized by sustained zero-order drug release producing median steady-state serum histrelin concentrations of approximately 0.2 to 0.4 ng/mL, with a terminal elimination half-life of the released peptide of approximately 4 hours, 92 percent subcutaneous bioavailability, and approximately 70 percent plasma protein binding [10, 14]. Metabolism is hepatic through peptidase-mediated degradation. The adverse-event profile is dominated by the pharmacological consequences of gonadal steroid suppression: hot flashes, reduced libido, erectile dysfunction or amenorrhea, and long-term bone mineral density reduction. Implant site reactions (bruising, pain, erythema) occur in approximately 50 percent of recipients. The initial flare phase carries specific risk in metastatic prostate cancer, which is mitigated by co-administration of an antiandrogen during the first 2 to 4 weeks of therapy. Postmarketing surveillance has identified rare but serious adverse events including pseudotumor cerebri, seizures, psychiatric symptoms (emotional lability, depression, suicidal ideation), and severe cutaneous adverse reactions. This monograph reviews the chemistry and synthesis, the biphasic GnRH receptor pharmacology, the comprehensive human pharmacokinetic record, the clinical evidence base across prostate cancer, central precocious puberty, endometriosis, and gender-affirming therapy indications, sourcing and quality verification, reconstitution and handling, stack interactions, adverse-event signal, and a comparative assessment of five GnRH agonist candidates against histrelin on five competency standards.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1397Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 10, 2026
Buserelin

Our opinion on this compoundEstablished workhorse

42/100

Pioneering GnRH superagonist that defined a drug class but has largely been superseded as a research frontier

Look, buserelin earned its place in pharmacology history. The Sandow group at Hoechst AG published the original characterization in 1976, and within a few years this thing was demonstrating something genuinely surprising: continuous administration of a potent GnRH agonist could paradoxically shut down the very axis it initially stimulated. That biphasic mechanism, acute flare followed by profound receptor desensitization and downregulation, was not obvious, and buserelin was one of the first compounds to prove it worked in humans. The 1980 intranasal castration paper was legitimately a milestone.

That was roughly 45 years ago. The GnRH superagonist class is now thoroughly mapped. Leuprolide, goserelin, triptorelin, nafarelin, histrelin. Each with its own formulation advantages, depot options, and regulatory footprints. Buserelin’s structural chemistry, the D-serine tert-butyl substitution at position 6 and the C-terminal ethylamide, is textbook material at this point. The Gq/11-PLC signaling cascade, the receptor internalization kinetics, the castrate testosterone levels at steady state: all of it is worked out in detail across multiple labs and decades. Thats not a criticism of the molecule, its just the reality of where the science sits.

The differentiation problem is real. In most of the markets that matter to a North American or Australian investigator, buserelin isn’t approved. Leuprolide holds that ground. If you’re building a research program around HPG axis suppression, androgen deprivation biology, or GnRH receptor pharmacology, buserelin isn’t your default probe. It’s one of many options, and not the globally dominant one. The veterinary Receptal formulation (Intervet/MSD) shows up in livestock reproductive research, which is a niche with genuine utility but not the frontier.

What buserelin does have going for it: robust multi-indication clinical evidence across prostate cancer, endometriosis, uterine fibroids, breast cancer, precocious puberty, and ART protocols in roughly 40 jurisdictions. The translational signal from GnRH agonism to clinically meaningful endpoints is about as clean as it gets in endocrinology. Medical castration is a real, reproducible, durable pharmacological effect with decades of outcome data behind it. That counts for something on the evidence and translational axes even if it doesn’t make buserelin exciting.

We think the honest read here is: this is a mature, well-validated workhorse in a crowded class where it isnt the category leader in most key markets. For investigators already working in GnRH biology or hormone-dependent oncology, it’s a legitimate tool with a real evidence base. For anyone looking for novel mechanisms or underexplored research territory, theres nothing here that isn’t better addressed by asking why you’re not using leuprolide or, if you want genuine novelty, looking at GnRH antagonists (degarelix, relugolix) where the pharmacology is less worked-over and the research questions are fresher.

Novelty

20

Mechanism promise

38

In-category differentiation

25

Evidence quality

68

Translational signal

72

Research bench value

42

Rationale Buserelin is a 1976-vintage approved drug with a thoroughly characterized biphasic GnRH receptor mechanism, solid multi-indication clinical evidence, and real translational impact, but it competes in a crowded class where leuprolide and goserelin dominate globally, its US/Australia non-approval limits sourcing, and the core biology it exploits is genuinely mature. Novelty and differentiation scores drag the overall into the low 40s, which is accurate for a compound whose main contribution was historical.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Synthetic gonadotropin-releasing hormone superagonist nonapeptide with paradoxical chronic suppression of pituitary-gonadal axis through GnRH receptor desensitization and downregulation

A synthetic nonapeptide analog of endogenous gonadotropin-releasing hormone bearing a D-serine(tert-butyl) substitution at position 6 and an ethylamide C-terminal modification, conferring 20- to 170-fold greater potency than native GnRH and resistance to enzymatic degradation, developed at Hoechst AG in the mid-1970s as one of the first clinically viable GnRH superagonists and now registered in approximately 40 jurisdictions for hormone-dependent prostate cancer, endometriosis, uterine fibroids, premenopausal breast cancer, central precocious puberty, and pituitary downregulation in assisted reproduction protocols.

Abstract

Buserelin ([D-Ser(tBu)6,des-Gly-NH2-10]GnRH ethylamide; CAS 57982-77-1, free base; 68630-75-1, acetate salt) is a synthetic nonapeptide analog of the hypothalamic decapeptide gonadotropin-releasing hormone (GnRH, also designated luteinizing hormone-releasing hormone, LHRH) first described by Sandow and colleagues at Hoechst AG in 1976 and approved for clinical use in 1984 [1, 2]. The compound incorporates two structural modifications to native GnRH that collectively confer superagonist potency and metabolic stability: replacement of glycine at position 6 with D-serine bearing a tert-butyl ether on the side-chain hydroxyl, which eliminates the principal endopeptidase cleavage site and introduces conformational rigidity favorable to receptor binding; and replacement of the C-terminal glycinamide (position 10) with an ethylamide, which further resists carboxypeptidase degradation. The resulting peptide binds the type I GnRH receptor with affinity approximately 20- to 170-fold greater than native GnRH and produces a biphasic pharmacological response that is the mechanistic foundation for all clinical applications [3, 4]. Acute administration stimulates pituitary gonadotroph secretion of luteinizing hormone and follicle-stimulating hormone, producing transient elevations in gonadal steroid output (the “flare” phase, lasting 7 to 14 days). Chronic continuous administration produces homologous desensitization of the GnRH receptor through receptor internalization, uncoupling from Gq/11-phospholipase C signaling, and transcriptional downregulation of GnRH receptor expression, resulting in profound and sustained suppression of gonadotropin secretion and a hypogonadal state equivalent to surgical castration in both sexes [5, 6]. This medical castration is reversible on cessation of treatment. Buserelin was the first GnRH agonist demonstrated to achieve medical castration in humans via intranasal administration, an observation reported by Sandow and colleagues in 1980 that established the clinical viability of non-injectable GnRH agonist therapy [2]. The compound is registered in approximately 40 jurisdictions across Europe, the United Kingdom, Canada, New Zealand, South Africa, Latin America, and Asia, but is not approved in the United States or Australia. Registered indications include hormone-responsive prostate cancer, endometriosis, uterine fibroids, premenopausal breast cancer, and pituitary downregulation as an adjunct to controlled ovarian hyperstimulation in assisted reproduction [7, 8, 9]. The compound is additionally used off-label for central precocious puberty and as a component of gender-affirming hormone therapy. Pharmacokinetics are characterized by negligible oral bioavailability due to gastrointestinal peptidase degradation, approximately 2.5 to 3.3 percent intranasal bioavailability, and approximately 70 percent subcutaneous bioavailability [10]. The plasma elimination half-life is 50 to 80 minutes after intravenous or subcutaneous administration and approximately 1 to 2 hours after intranasal dosing. Protein binding is low (approximately 15 percent). Metabolism occurs principally through pyroglutamyl peptidase and chymotrypsin-like endopeptidase activity in the liver, kidneys, and gastrointestinal tract, with approximately 50 percent of the administered dose recovered unchanged in urine [10, 11]. Formulations include aqueous solution for subcutaneous injection and intranasal spray (requiring multiple daily administrations) and sustained-release subcutaneous implants providing 2- or 3-month depot delivery. The adverse-event profile is dominated by the pharmacological consequences of gonadal steroid suppression: hot flashes, reduced libido, erectile dysfunction or vaginal dryness, and long-term bone mineral density reduction. The initial flare phase carries specific risk in metastatic prostate cancer (bone pain exacerbation, spinal cord compression, ureteral obstruction), which is mitigated clinically by co-administration of an antiandrogen during the first 2 to 4 weeks of therapy. This monograph reviews the chemistry and synthesis, the biphasic GnRH receptor pharmacology, the comprehensive human pharmacokinetic record, the clinical evidence base across prostate cancer, endometriosis, uterine fibroids, breast cancer, precocious puberty, and assisted reproduction indications, sourcing and quality verification, reconstitution and handling, stack interactions, adverse-event signal, and a comparative assessment of five GnRH agonist candidates against buserelin on five competency standards.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1395Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 10, 2026
Mecasermin

Our opinion on this compoundEstablished, active research

53/100

FDA-approved rhIGF-1 with a mechanistically necessary orphan niche and a genuinely interesting Rett syndrome signal

Look, mecasermin is the real thing in a narrow sense: it’s actual recombinant human IGF-1, FDA-approved in 2005 for severe primary IGF-1 deficiency, which mostly means Laron syndrome patients whose growth hormone receptors simply don’t function. In that context the pharmacology is essentially irrefutable. You can’t give these patients GH because the receptor is dead; you give them downstream IGF-1 directly. The Tercica/Genentech development story is clean, the regulatory file is solid, and the phase 3 data for SPIGFD does what it says on the tin. Priority review, EMA follow-on in 2007. The approved indication is textbook.

The mechanism is PI3K/Akt/mTOR and Ras/MAPK/ERK downstream of the type 1 IGF-1 receptor. Known thoroughly. What makes mecasermin worth watching right now isn’t the growth biology but the neurotrophic and neurodevelopmental angles. The Kaufmann group at Boston Children’s and Pini’s group in Bologna have run independent phase 2 trials in Rett syndrome, an X-linked neurodevelopmental condition caused by MECP2 mutation. The rationale is that IGF-1 signaling drives synaptogenesis and synaptic maturation, and Rett patients show suppressed IGF-1 expression. Both trials returned real, if modest, improvements in breathing irregularity, social responsiveness, and hand use. That independent replication across two groups in a rare pediatric disease is meaningful; you dont get that often in the orphan space.

The ALS chapter is less encouraging. Multiple trials over the years have produced essentially negative results, which limits enthusiasm for broader neurodegeneration applications. The bench value comes primarily from mecasermin being the only full-length, FDA-characterized rhIGF-1 in regular clinical use. For investigators studying IGF-1R biology in a human-translatable context, thats a genuine asset. That said, most preclinical lab work on IGF-1 receptor pharmacology uses IGF-1 LR3, which has substantially better pharmacokinetics for in vitro and in vivo applications. Mecasermin binds insulin-like growth factor binding proteins extensively, meaning free IGF-1 levels are considerably lower than total protein measurements suggest, which complicates dose interpretation and experimental design.

Honestly, the novelty here is mostly downstream of the underlying IGF-1 axis biology rather than the compound itself. What we like: the Rett syndrome signal is genuine, the independent replication is the strongest thing on its evidence card, and the compound is exceptionally well-characterized. What we dont like: the approved indication is a small orphan niche, the investigational evidence sits at phase 2, hypoglycemia is a serious practical constraint that narrows the usable dose range, and for pure bench work IGF-1 LR3 is the more practical probe. For a group focused on IGF-1 receptor signaling in neurodevelopment, mecasermin is a legitimate and well-documented tool. For everyone else it’s a historically important compound with one clean narrow win and some unfinished business in pediatric neurology.

Novelty

38

Mechanism promise

45

In-category differentiation

62

Evidence quality

65

Translational signal

60

Research bench value

52

Rationale Mecasermin scores modestly on novelty because the IGF-1 axis and its downstream PI3K/Akt/mTOR signaling are thoroughly mapped, but the independent replication in Rett syndrome (Kaufmann and Pini groups) and its status as the only FDA-grade full-length rhIGF-1 anchor real differentiation and translational value; ALS failures and IGF-1 LR3’s dominance in bench work cap enthusiasm.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Recombinant human insulin-like growth factor 1 (rhIGF-1), a 70-amino-acid single-chain polypeptide with three intramolecular disulfide bonds

A recombinant analog of endogenous insulin-like growth factor 1 developed at Genentech and commercialized by Tercica (later Ipsen) for the treatment of severe primary IGF-1 deficiency, distinguished from growth hormone replacement by its direct activation of the type 1 IGF-1 receptor and its investigational applications in neuroprotection, neurodevelopmental disorders, and metabolic disease.

Abstract

Mecasermin is recombinant human insulin-like growth factor 1 (rhIGF-1), a 70-amino-acid, 7649-dalton non-glycosylated polypeptide produced in Escherichia coli by recombinant DNA technology. The amino acid sequence of mecasermin is identical to that of endogenous human IGF-1, a peptide hormone synthesized principally in the liver under the transcriptional control of growth hormone and serving as the primary mediator of postnatal somatic growth, skeletal maturation, and metabolic homeostasis. Mecasermin is the active pharmaceutical ingredient in Increlex (Ipsen), the only therapy approved by the United States Food and Drug Administration (August 2005, priority review) and by the European Medicines Agency (2007) for the long-term treatment of growth failure in pediatric patients with severe primary insulin-like growth factor 1 deficiency (SPIGFD), a condition most classically represented by Laron syndrome (growth hormone receptor deficiency) and by growth hormone gene deletion with neutralizing antibodies to exogenous growth hormone.

The mechanism of action is direct agonism of the type 1 IGF-1 receptor (IGF-1R), a transmembrane receptor tyrosine kinase structurally homologous to the insulin receptor. Ligand binding activates autophosphorylation of the intracellular kinase domain and recruitment of insulin receptor substrate (IRS) adapter proteins, leading to bifurcated downstream signaling through the phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway (metabolic, anti-apoptotic, and translational outcomes) and the Ras/Raf/mitogen-activated protein kinase (MAPK/ERK) pathway (mitogenic, proliferative, and differentiative outcomes). In the growth plate, IGF-1R activation stimulates chondrocyte proliferation and hypertrophy in the proliferative and hypertrophic zones of the epiphyseal cartilage, driving longitudinal bone growth through endochondral ossification. The metabolic actions include stimulation of glucose uptake, amino acid incorporation into protein, fatty acid uptake, and suppression of hepatic glucose output, producing a composite anabolic and mildly hypoglycemic pharmacology.

Pharmacokinetics following subcutaneous injection are characterized by near-complete bioavailability, a time to peak plasma concentration of approximately 2 hours, and a terminal elimination half-life that is critically dependent on circulating levels of IGF-binding protein 3 (IGFBP-3) and the acid-labile subunit (ALS). In patients with severe primary IGF-1 deficiency, who characteristically have low IGFBP-3 and ALS concentrations, the terminal half-life is approximately 5.8 hours; in healthy individuals with normal binding protein levels, the half-life extends to approximately 19 hours owing to sequestration in the 150-kilodalton ternary complex of IGF-1, IGFBP-3, and ALS. The volume of distribution is approximately 0.257 liters per kilogram. Clearance is inversely proportional to IGFBP-3 concentration and is estimated at 0.04 liters per hour per kilogram at an IGFBP-3 level of 3 micrograms per milliliter. Metabolism is predominantly lysosomal, principally in the liver and kidneys, with degradation to amino acids; less than 0.1 percent of administered drug is excreted unchanged in urine.

The pivotal clinical evidence base consists of five open-label, single-arm studies in 71 pediatric patients with SPIGFD treated for a mean duration of 3.9 years (274 subject-years of exposure). First-year height velocity increased from a baseline of 2.6 centimeters per year to 8.0 centimeters per year (p less than 0.0001), with sustained growth acceleration over 8 or more years of continuous treatment. The principal adverse event is hypoglycemia, reported in 42 percent of subjects; severe hypoglycemia requiring assistance occurred in 5 subjects, and hypoglycemic seizures or loss of consciousness occurred in 4 subjects. Hypoglycemia is mitigated by administration within 20 minutes of a meal or snack. Other notable adverse events include tonsillar and adenoidal hypertrophy (15 percent), injection site lipohypertrophy, and intracranial hypertension with papilledema (3 subjects). Long-term safety monitoring has not identified an increased incidence of malignancy at approved doses. Investigational applications of mecasermin extend to Rett syndrome (Phase 1, with improvement in apnea and neurobehavioral parameters), amyotrophic lateral sclerosis (negative in controlled trials), and various neuroprotective contexts supported by the neurotrophic properties of IGF-1.

This monograph reviews the chemistry and recombinant production of mecasermin; the IGF-1R signaling pharmacology in molecular detail; the comprehensive pharmacokinetic record including binding protein dependence; the clinical evidence base across growth failure, neuroprotection, and metabolic indications; sourcing and quality verification for research-grade material; reconstitution and handling; stack-interaction considerations; adverse-event signal; and a comparative assessment of five alternative growth-promoting or IGF-1-axis compounds against mecasermin on five competency standards (novelty, effect size, promising potential, side-effect profile, and overall validation).

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1422Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 10, 2026
Maritide

Our opinion on this compoundNovel frontier

76/100

First-in-class bispecific antibody-peptide conjugate betting on GIPR antagonism with compelling Phase 2 weight-loss signal

Look, the incretin space is crowded, but maritide is doing something genuinely different from every other molecule in it. While tirzepatide bets that GIP receptor agonism enhances GLP-1 action, maridebart cafraglutide takes the opposite position: block GIPR and see what happens when GLP-1R gets all the floor. The fact that both approaches produce serious weight loss in humans is itself a research finding worth sitting with, because it says something important and still-contested about how GIP signaling actually works in metabolic disease. That mechanistic debate is live, and maritide is one of the primary instruments for settling it.

The molecular architecture earns its novelty points on its own terms. This isnt a dual peptide agonist or a bispecific small molecule. Its a fully human IgG2 monoclonal antibody with two covalently attached GLP-1 agonist peptide analogues, which gives a terminal half-life around 21 days after subcutaneous dosing. Thats roughly three times longer than semaglutide’s weekly profile, and it represents a distinct pharmacological regime that lets you ask different questions about receptor occupancy duration, downstream signaling adaptation, and what chronic receptor blockade looks like across adipose versus central tissue compartments.

The Phase 2 data (NCT05669599, 592 adults, 52 weeks) is the most interesting part of the current evidence base. Up to 20 percent weight loss in participants without type 2 diabetes, HbA1c reductions of up to 2.2 percentage points, and a no-plateau finding at 52 weeks. Most GLP-1 agents show flattening curves by mid-study. If that non-plateau signal holds in Phase 3, thats a real clinical differentiation. The Phase 2 also reported fat-preferential mass loss without clinically significant bone mineral density changes, which addresses a concern that has been following the whole class since semaglutide’s lean mass signal appeared in STEP. The gastrointestinal tolerability data at the dose-escalated arms is also more favorable than earlier versions of the protocol.

What we don’t like: this is still a single-developer compound with no independent academic replication of the core GIPR antagonism mechanism. The downstream biology of chronically blocking GIP while agonizing GLP-1R at high receptor occupancy is not fully worked out. Amgen initiated the MARITIME Phase 3 program in 2025, but primary readouts arent expected until early 2027, so the evidence base is going to sit at Phase 2 for a while. Retatrutide and tirzepatide both have further-developed clinical profiles right now, and whether GIPR antagonism matches or beats dual agonism is genuinely unanswered.

For researchers working in incretin pharmacology, body composition biology, or antibody-peptide conjugate engineering, maritide is one of the more interesting compounds in the current landscape. The bispecific format alone is worth studying as an architecture. We think the GIPR antagonism angle is the more intellectually interesting mechanistic bet in the space right now, and the Phase 2 signal gives real reason to follow Phase 3 closely.

Novelty

82

Mechanism promise

84

In-category differentiation

84

Evidence quality

62

Translational signal

70

Research bench value

60

Rationale The bispecific IgG2-peptide conjugate format and the GIPR antagonism pharmacological bet (opposite to tirzepatide’s agonism) earn genuine novelty and differentiation scores; evidence and translational axes are constrained by the Phase 2-only evidence base, with MARITIME Phase 3 readouts not expected until early 2027.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Bispecific peptide-antibody conjugate combining GLP-1 receptor agonism with GIP receptor antagonism

A first-in-class bispecific antibody-peptide conjugate developed at Amgen that pairs a fully human monoclonal glucose-dependent insulinotropic polypeptide receptor antagonist antibody with two covalently linked glucagon-like peptide 1 analogue agonist peptides, yielding a long-acting once-monthly injectable for chronic weight management distinguished from existing incretin therapeutics by simultaneous GIP receptor blockade and an approximately 21-day elimination half-life.

Abstract

Maridebart cafraglutide (MariTide; development code AMG 133) is a first-in-class bispecific peptide-antibody conjugate engineered at Amgen by covalent attachment of two glucagon-like peptide 1 (GLP-1) receptor agonist peptide analogues to a fully human immunoglobulin G2 (IgG2) monoclonal antibody that functions as a potent antagonist of the glucose-dependent insulinotropic polypeptide receptor (GIPR). The molecule was designed to exploit the additive weight-loss pharmacology of simultaneous GLP-1 receptor (GLP-1R) activation and GIP receptor blockade, a mechanistic combination that in preclinical diet-induced obese mouse and cynomolgus monkey models produced greater body-weight reduction than either moiety alone. In cell-based functional assays the compound demonstrates GLP-1R agonist activity with EC50 values of 24.4 picomolar (human), 5.7 picomolar (cynomolgus monkey), 2.4 picomolar (rat), and 123 picomolar (mouse), and GIPR antagonist activity with IC50 values of 46.4 nanomolar (human), 26.5 nanomolar (cynomolgus monkey), and 822.3 nanomolar (rat) [1, 2]. The antibody scaffold confers a terminal elimination half-life of approximately 21 days in humans after subcutaneous administration, approximately three-fold longer than the longest-acting approved once-weekly GLP-1 receptor agonists, and supports once-monthly or less frequent dosing [1]. In a Phase 1 randomized, double-blind, placebo-controlled single- and multiple-ascending-dose study (NCT04478708) in 163 adults with obesity, maridebart cafraglutide produced dose-dependent weight loss of up to 14.5 percent at 12 weeks with weight loss maintained for up to 150 days after the final dose, accompanied by an acceptable safety and tolerability profile in which gastrointestinal adverse events (nausea, vomiting) were predominantly mild and transient [1]. A Phase 2 dose-ranging study (NCT05669599) in 592 adults with obesity with or without type 2 diabetes randomized to subcutaneous maridebart cafraglutide at 140, 280, or 420 mg every four weeks or 420 mg every eight weeks versus placebo for 52 weeks demonstrated mean weight loss of 12.3 to 20 percent in participants without type 2 diabetes and 8.4 to 17 percent in participants with type 2 diabetes, with HbA1c reductions of up to 2.2 percentage points, without evidence of a weight-loss plateau at 52 weeks [3, 4]. The Phase 2 study further reported no clinically significant changes in bone mineral density and body-composition data indicating that the majority of weight lost was fat mass rather than lean tissue. Gastrointestinal adverse events were the most common treatment-emergent events and were mitigated by dose escalation from a lower starting dose; discontinuation rates due to gastrointestinal events were approximately 8 percent with dose escalation compared with 12 to 27 percent without [3, 4]. Amgen initiated the Phase 3 MARITIME program in 2025, comprising chronic weight management trials (MARITIME-1 in obesity without type 2 diabetes, MARITIME-2 in obesity with type 2 diabetes) with planned 72-week treatment duration and primary readouts expected in early 2027, as well as planned Phase 3 cardiovascular outcomes, heart failure, and obstructive sleep apnea studies [5, 6]. The compound is not approved by any regulatory authority as of the monograph date. This monograph documents the molecular design and structural biology of the peptide-antibody conjugate; the dual-receptor pharmacology at GLP-1R and GIPR in molecular and cellular detail; the preclinical pharmacology in rodent and primate models; the comprehensive human pharmacokinetic record; the clinical evidence base across Phase 1 and Phase 2 obesity and type 2 diabetes endpoints; sourcing and handling considerations; stack-interaction implications; adverse-event profile; and a comparative assessment of five incretin-class obesity therapeutics against maridebart cafraglutide on five competency standards.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1412Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 10, 2026
Mecasermin rinfabate

Our opinion on this compoundEstablished workhorse

44/100

Elegant but withdrawn IGF-1 binary complex whose science held up while the market window closed

Look, mecasermin rinfabate is one of those compounds where the science was genuinely solid and the story ended for the wrong reasons. The binary complex approach (pairing rhIGF-1 with rhIGFBP-3 in equimolar ratios to replicate the dominant physiological form of circulating IGF-1) was clever when Celtrix developed it in the late 1990s. The pharmacokinetic rationale holds up: free IGF-1 clears in roughly 10 to 20 minutes, while the binary complex extends that to 13 to 21 hours by associating with endogenous acid-labile subunit to reconstitute the normal ternary reservoir. That’s real pharmacology, not marketing.

What we dont like is that by 2026, this is a 20-year-old story. iPLEX was FDA-approved in December 2005 for severe primary IGF-1 deficiency, briefly marketed, then pulled in March 2007 following patent litigation with Tercica over Increlex. The withdrawal was legal, not scientific; the mechanism was never challenged. But that distinction doesnt help much from a research calendar standpoint. Mecasermin rinfabate has spent nearly two decades as a research-grade artifact rather than an active pharmaceutical. The IGF-1/IGFBP-3 axis biology is textbook at this point, and the clinical population it originally served remains Increlex territory.

The post-withdrawal programs are worth knowing about but dont dramatically change the picture. The ALS push was scientifically motivated: IGF-1 signals through PI3K/Akt and MAPK pathways in motor neurons, and rescue effects in SOD1 transgenic rodent models were reproducible enough to justify clinical evaluation. The trial results were inconclusive, though, and the program stalled. The neonatal work around retinopathy of prematurity is more alive; there’s genuine signal in small studies of IGF-1 supplementation in preterm neonates, and the biology (IGF-1 as a developmental cue for vascular normalization in the immature retina) is real. The evidence base remains limited, mostly single-center or small-consortium, without the multi-lab replication a serious bench program needs to lean on.

As a research tool, rinfabate has one concrete advantage over free rhIGF-1: the extended pharmacokinetics let you study sustained IGF-1 axis activation without the hypoglycemia confound that complicates mecasermin studies. That’s real bench utility for groups working on IGF-1’s role in neurodegeneration or neonatal vascular biology. But its not irreplaceable; mecasermin with careful dosing protocols covers most of the same biology, and downstream pathway probes (PI3K inhibitors, IGF-1R knockdowns) are often more useful for mechanistic work anyway. For most investigators, mecasermin rinfabate is an interesting historical footnote rather than a primary tool. The original pharmacological concept was genuinely elegant. The research window just passed.

Novelty

28

Mechanism promise

42

In-category differentiation

45

Evidence quality

58

Translational signal

52

Research bench value

40

Rationale Mecasermin rinfabate solved a genuine PK problem with physiological elegance and earned FDA approval, but a 2007 patent-litigation withdrawal left it dormant for nearly two decades; the ALS and neonatal successor programs have produced modest, unreplicated signal that keeps it interesting for niche investigators without elevating it to active-research priority.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Recombinant human insulin-like growth factor-1 and insulin-like growth factor binding protein-3 equimolar binary complex (rhIGF-1/rhIGFBP-3)

A recombinant equimolar binary protein complex of human IGF-1 and its principal binding protein IGFBP-3, developed by Insmed as iPLEX for subcutaneous replacement therapy in severe primary IGF-1 deficiency and subsequently investigated in amyotrophic lateral sclerosis and complications of extreme prematurity.

Abstract

Mecasermin rinfabate (International Nonproprietary Name; brand name iPLEX) is a pharmaceutical-grade equimolar binary complex of recombinant human insulin-like growth factor-1 (rhIGF-1, 70 amino acids, 7,649 Da) and recombinant human insulin-like growth factor binding protein-3 (rhIGFBP-3, 264 amino acids, approximately 28,700 Da unglycosylated), produced in Escherichia coli expression systems and formulated for subcutaneous injection at a combined molecular weight of approximately 36,381 daltons. The complex was designed to replicate the physiological binary association of IGF-1 with its most abundant circulating binding protein, thereby extending the plasma half-life of administered IGF-1 from approximately 10 to 20 minutes (free rhIGF-1) to approximately 13 to 21 hours (complexed form), reducing hypoglycemic risk relative to unbound IGF-1, and enabling once-daily subcutaneous dosing in contrast to the twice-daily regimen required for mecasermin (rhIGF-1 alone, marketed as Increlex). Upon subcutaneous administration, the binary complex associates with endogenous acid-labile subunit (ALS) to form the approximately 150 kDa ternary complex that represents the principal physiological reservoir of circulating IGF-1, thereby normalizing the IGF-1 axis in patients with deficient endogenous production.

The compound received United States Food and Drug Administration approval on December 12, 2005 (NDA 021884) for the treatment of growth failure in children with severe primary insulin-like growth factor-1 deficiency (Primary IGFD) or with growth hormone gene deletion who have developed neutralizing antibodies to growth hormone. The approved dose range was 0.5 to 2.0 mg/kg administered once daily by subcutaneous injection, titrated to achieve physiological IGF-1 levels measured 8 to 18 hours post-dose. Clinical development was conducted in two cohort studies enrolling 36 children and adolescents with primary IGFD, predominantly growth hormone receptor deficiency (Laron syndrome), demonstrating statistically significant dose-dependent increases in height velocity from a pre-treatment baseline of approximately 3 to 4 cm/year to 6 to 9 cm/year during the first year of treatment.

The commercial trajectory of mecasermin rinfabate was truncated by patent litigation. In March 2007, Insmed Incorporated settled a patent infringement action brought by Tercica (the manufacturer of mecasermin/Increlex) by agreeing to withdraw iPLEX from the United States market for all short stature indications and to abandon its European regulatory application for these uses. The settlement extinguished the primary commercial indication. Insmed subsequently investigated mecasermin rinfabate in amyotrophic lateral sclerosis (ALS) under both clinical trial and compassionate-use frameworks; a Phase II randomized controlled trial in 330 ALS patients failed to demonstrate benefit on muscle strength, need for tracheostomy, or survival at the end of a two-year treatment period. More recently, the rhIGF-1/rhIGFBP-3 complex (under the development name of the successor product) has been investigated by Shire (now Takeda) and collaborators in extremely preterm infants for prevention of retinopathy of prematurity and other complications of prematurity, with a Phase 2 randomized controlled trial (NCT01096784) demonstrating a 53 percent decrease in severe bronchopulmonary dysplasia but no reduction in retinopathy of prematurity severity.

The pharmacology of mecasermin rinfabate is that of its constituent IGF-1 moiety acting through the type 1 IGF receptor (IGF-1R), a transmembrane receptor tyrosine kinase that activates the phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase (MAPK/ERK) signaling cascades to promote linear growth, cellular proliferation, differentiation, and survival. The IGFBP-3 moiety serves as a pharmacokinetic modulator, extending half-life and buffering against acute hypoglycemia, while also exerting IGF-independent effects including proapoptotic activity through nuclear receptor interactions and antiproliferative signaling in certain cellular contexts. The principal adverse events at approved doses are hypoglycemia (31 percent), headache (22 percent), arthralgia, injection site reactions, and lymphadenopathy. Safety data beyond 21 months of continuous treatment have not been established. This monograph reviews the molecular composition, development history, mechanism of action, pharmacokinetics, clinical evidence base across all studied indications, handling considerations, adverse-event profile, and a comparative assessment of five IGF-1 axis therapeutics against mecasermin rinfabate on five competency standards.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1423Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 10, 2026

←Previous Page

1 … 26 27 28 29 30 … 69

Bench-grade research compounds. Cited research. Verified COAs.

kodiac.bio

Explore

Shop
Monographs
Lab Results
About
Affiliate program
Affiliate handbook

Account

Cart
My account

Help

Compliance
Contact

Quarterly dispatch

New batches and new monographs only. Unsubscribe in one click.

Write to us from the contact page to join the list.

Kodiac biolabs sells research compounds for in vitro and in vivo investigative purposes only. Products are not for human or veterinary consumption. Not for medical, diagnostic, or therapeutic use. By using this site you confirm you are acquiring research compounds for research purposes only.

Kodiac biolabs is not affiliated with the U.S. Food and Drug Administration. Products are research reagents, have not been evaluated by the FDA, and are not intended to diagnose, treat, cure, or prevent any disease.

© 2026 Kodiac biolabs LLC. All rights reserved.